Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$4.78 +0.4%	$4.42	$3.39 ▼ $16.00	$51.76M	0.7	61,353 shs	92,801 shs
CYCC Cyclacel Pharmaceuticals	$0.33 -5.4%	$2.10	$0.25 ▼ $39.84	$7.86M	0.24	424,670 shs	472,749 shs
OTLK Oncobiologics	$1.60 -8.6%	$1.68	$0.87 ▼ $9.25	$53.71M	0.31	821,645 shs	2.90 million shs
QNTM Quantum Biopharma	$21.72 +2.8%	$13.92	$2.70 ▼ $38.25	$63.15M	0.55	937,409 shs	297,615 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	+3.02%	+28.49%	-43.50%	-64.17%
CYCC Cyclacel Pharmaceuticals	0.00%	-2.90%	-79.31%	-93.08%	-98.92%
OTLK Oncobiologics	0.00%	-6.16%	-11.11%	+21.21%	-77.62%
QNTM Quantum Biopharma	0.00%	-37.94%	+72.66%	+153.74%	+2,171,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.1842 of 5 stars	3.5	3.0	0.0	0.0	2.7	1.7	1.3
CYCC Cyclacel Pharmaceuticals	0.5114 of 5 stars	0.0	3.0	0.0	0.0	2.0	1.7	0.0
OTLK Oncobiologics	2.3922 of 5 stars	3.4	3.0	0.0	0.0	3.3	0.0	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	527.62% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	500.00% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNTM, OTLK, AVTX, and CYCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	117.65	N/A	N/A	$12.80 per share	0.37
CYCC Cyclacel Pharmaceuticals	$40K	196.61	N/A	N/A	($3.93) per share	-0.08
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$4.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$56.00	N/A	∞	N/A	-18,150.00%	-3,648.09%	-155.99%	7/1/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)
QNTM Quantum Biopharma	-$14.20M	-$15.98	N/A	N/A	N/A	N/A	-155.20%	-94.90%	8/13/2025 (Estimated)

Latest QNTM, OTLK, AVTX, and CYCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
4/2/2025	Q4 2024	CYCC Cyclacel Pharmaceuticals	-$4.64	-$5.28	-$0.64	-$0.33	$0.01 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Latest QNTM, OTLK, AVTX, and CYCC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/28/2025	CYCC Cyclacel Pharmaceuticals		$2.40		4/29/2025	4/29/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	22.61	22.61
CYCC Cyclacel Pharmaceuticals	N/A	5.60	5.60
OTLK Oncobiologics	N/A	0.72	0.57
QNTM Quantum Biopharma	N/A	0.96	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CYCC Cyclacel Pharmaceuticals	23.58%
OTLK Oncobiologics	11.20%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	3.03%
CYCC Cyclacel Pharmaceuticals	96.90%
OTLK Oncobiologics	4.80%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.50 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	14	23.76 million	737,000	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A

QNTM, OTLK, AVTX, and CYCC Headlines

Recent News About These Companies

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering - Morningstar

June 27 at 7:05 PM | morningstar.comM

Quantum BioPharma Announces Private Placement

June 27 at 4:30 PM | globenewswire.com

Best Cannabis Stocks To Watch Today - June 26th

June 26 at 2:04 PM | marketbeat.com

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

June 26 at 7:30 AM | globenewswire.com

Cannabis Stocks To Research - June 25th

June 25, 2025 | marketbeat.com

Q1 Earnings Forecast for QNTM Issued By Singular Research

June 24, 2025 | americanbankingnews.com

Top Cannabis Stocks To Keep An Eye On - June 23rd

June 23, 2025 | marketbeat.com

What is Singular Research's Estimate for QNTM Q1 Earnings?

June 23, 2025 | marketbeat.com

Quantum Biopharma (NASDAQ:QNTM) Upgraded at Singular Research

June 21, 2025 | marketbeat.com

Cannabis Stocks To Follow Today - June 20th

June 20, 2025 | marketbeat.com

Unbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)

June 19, 2025 | morningstar.comM

Quantum, CyberCatch, Kodiak at 52-Week Highs on News

June 18, 2025 | ca.finance.yahoo.com

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

June 18, 2025 | newsfilecorp.comN

Keg, LQWD, Quantum at 52-Week Highs on News

June 17, 2025 | baystreet.ca

Cannabis Stocks To Add to Your Watchlist - June 17th

June 17, 2025 | marketbeat.com

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

June 17, 2025 | globenewswire.com

Quantum BioPharma plans special dividend tied to legal action

June 14, 2025 | investing.com

Best Cannabis Stocks To Add to Your Watchlist - June 13th

June 13, 2025 | marketbeat.com

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

June 13, 2025 | globenewswire.com

Quantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin Purchase

June 10, 2025 | bitcoinmagazine.com

Quantum BioPharma clarifies misinformation on stock name, RTO rumors

June 4, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, OTLK, AVTX, and CYCC Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$4.78 +0.02 (+0.42%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.78 0.00 (-0.10%)

As of 06/27/2025 06:09 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$0.33 -0.02 (-5.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.34 +0.01 (+1.81%)

As of 06/27/2025 07:14 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Oncobiologics NASDAQ:OTLK

$1.60 -0.15 (-8.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.66 +0.06 (+3.75%)

As of 06/27/2025 05:57 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Quantum Biopharma NASDAQ:QNTM

$21.72 +0.60 (+2.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.62 -0.11 (-0.48%)

As of 06/27/2025 07:56 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time